Clinical trials: Patients With Bipolar Disorders
Bipolar Disorder
A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
In period I, the treatment effect of FK949E was compared with that of placebo in a blind manner in bipolar disorder patients with major depressive episodes. In period II, the long-term safety and efficacy of FK949E was evaluated.
- Trial name
- NCT01725308
- Testing
- FK949E
- Where
- 98 sites in Japan
- Volunteers
- 431 people
- Sponsor
- Astellas Pharma Inc
Bipolar Disorder
Study of Aripiprazole in Patients With Bipolar I Disorder
The purpose of this research study is to compare the efficacy of aripiprazole with placebo in combination with lithium or valproate monotherapy, in the treatment of bipolar I patients with manic or mixed episodes.
- Trial name
- NCT00257972
- Testing
- aripiprazole
- Where
- 90 sites in United States, Australia and 15 more
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar I Disorder
A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
To assess the safety and efficacy of long-term administration of aripiprazole in combination with mood stabilizer (lithium or valproate) in an unblinded manner in patients with Bipolar I Disorder experiencing a manic or mixed…
- Trial name
- NCT00606229
- Testing
- Aripiprazole
- Where
- 5 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Bipolar Affective Disorder
Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in…
- Trial name
- NCT07858565
- Testing
- Quetiapine (drug), quetiapine + aripiprazole, quetiapine + haloperidol
- Where
- Bosnia and Herzegovina
- Volunteers
- 500 people
- Sponsor
- Bosnalijek D.D
Bipolar Disorder
Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness
To demonstrate the difference between Abilify with Depakote vs. Placebo with Depakote in 24-week treatment in patients with remission status after Abilify with Depakote in the 6-week study of acute mania in patients with bipolar…
- Trial name
- SMART-M (NCT00545675)
- Testing
- Abilify(aripiprazole), Depakote (divalproate)
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Bipolar Depression
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe when added to treatment with lithium or Divalproex for the treatment of patients with bipolar I depression.
- Trial name
- NCT00868452
- Testing
- lurasidone + (lithium or divalproex)
- Where
- 71 sites in United States, Czechia and 8 more
- Volunteers
- 348 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bipolar Disorder, New Occurred Episode
Management of Index Episode in Patients With Bipolar Disorder Treated by Seroquel XR
The primary purpose of the study is to explore management of symptomatology in patients with bipolar disorder that experience a new manic,depressive or mixed episode and are treated with Seroquel XR monotherapy/adjuctive, in…
- Trial name
- NCT01029145
- Where
- 30 sites in Romania
- Volunteers
- 537 people
- Sponsor
- AstraZeneca
Benign Prostatic Hypertrophy
Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP
To verify the safety and efficacy of the use of the plasma vaporisation button in Transurethral Vapor Enucleation and Resection of the prostate (TVERP) for treatment of Benign prostatic hypertrophy (BPH) patients with prostate…
- Trial name
- NCT04398420
- Testing
- TVERP, TURis, HoLEP
- Where
- 3 sites in China
- Volunteers
- 29 people
- Sponsor
- Olympus Surgical Technologies Europe
Depression, Bipolar
Olanzapine Treatment of Patients With Bipolar I Disorder
The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.
- Trial name
- NCT00510146
- Testing
- Olanzapine
- Where
- 16 sites in China, Japan and 1 more
- Volunteers
- 514 people
- Sponsor
- Eli Lilly and Company
Acute Mania in Bipolar Disorder
Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
To compare the efficacy and safety of quetiapine fumarate given as mono-therapy or adjunct therapy to lithium in the treatment of patients with acute mania in bipolar disorder.
- Trial name
- MANIA (NCT00672490)
- Testing
- Quetiapine Fumarate, Lithium
- Where
- 16 sites in China
- Volunteers
- 376 people
- Sponsor
- AstraZeneca
Bipolar Disorder, Depression, Bipolar
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
- Trial name
- NCT00060489
- Testing
- SEROQUEL (quetiapine fumarate) Tablets
- Where
- 27 sites in United States
- Sponsor
- AstraZeneca
Bipolar Disorder
3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes).
- Trial name
- NCT00159796
- Testing
- Asenapine, Olanzapine
- Volunteers
- 489 people
- Sponsor
- Organon and Co
Affective Psychosis, Bipolar, Manic Disorder
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks.
- Conditions
- Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania
- Trial name
- NCT00422123
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 51 sites in United States
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Schizophrenia, Bipolar Disorder
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.
- Trial name
- NCT00216723
- Testing
- Aripiprazole
- Where
- 2 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Bipolar Disorder
Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey
A registry study to identify the patient-diagnosis-treatment characteristic profile of patients with bipolar disorder in Turkey.
- Trial name
- NCT00660712
- Where
- 19 sites in Turkey (Türkiye)
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Bipolar Disorder, Schizophrenia
A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)
The basic hypothesis of this trial is that forgetfulness and failure to establish a routine that facilitates medication adherence are prominent reasons for non-adherence.
- Trial name
- SEQUEL (NCT00533260)
- Where
- 35 sites in Netherlands
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode
The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.
- Trial name
- NCT00080314
- Testing
- Aripiprazole
- Where
- 28 sites in United States
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Depression
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major…
- Trial name
- NCT03249376
- Testing
- Lumateperone
- Where
- 47 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar Depression
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective…
- Trial name
- PREVAIL3 (NCT01284517)
- Testing
- Lurasidone
- Where
- 75 sites in United States, Canada and 8 more
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bipolar Depression, Suicidal Ideation
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketamine HCL) for rapid stabilization of…
- Trial name
- SBD-ASIB (NCT03396068)
- Testing
- NRX-101, Lurasidone HCl
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- NeuroRx, Inc.